Advanced Drug Delivery Reviews Submission Guide

Source: Clarivate JCR 2024, Elsevier editorial disclosures (accessed April 2026).

Source: Advanced Drug Delivery Reviews author guidelines.

Use this page when deciding:

• whether your topic fits a likely future thematic issue

• whether your standing supports a Guest Editor invitation

• how to make pre-invitation contact

• specific topic and relevance to current drug-delivery priorities

• author credentials with primary-research evidence

• a brief discussion of why this topic merits a thematic-issue treatment

Invited authors writing for an Advanced Drug Delivery Reviews theme issue submit these:

• comprehensive review manuscript file (typical length 25-50 pages)

• forward-looking identification of major conceptual and technological challenges in the field

• evaluation of triumphs and shortcomings in current conceptual and technical approaches

• conclusions section with expert recommendations on how to address the field's open questions

• comprehensive reference list weighted toward primary literature, not other review papers

• figures synthesizing the field (mechanism schematics, comparison tables, design-space maps)

• author CRediT contribution statement

• declaration of competing interests with detail on industry consulting and licensing relationships

• declaration of generative AI use in the writing process

• for revised submissions, point-by-point reviewer response

For Advanced Drug Delivery Reviews submissions, the most common artifact-related issue at the invited-manuscript stage is conclusions sections that summarize the review rather than identify open questions. The Editor-in-Chief and Executive Editors explicitly ask for forward-looking conclusions with expert recommendations; descriptive recap sections trigger major-revision requests on what would otherwise be acceptable manuscripts.

Across Manusights submission reviews for Advanced Drug Delivery Reviews, the workflow runs through a four-stage timeline that differs from standard journals because invitation precedes manuscript work.

Day 0 to 14: Pre-invitation contact and topic vetting

Authors propose a theme-issue topic to one of the Executive Editors by email. Editors evaluate fit with the journal's thematic calendar, scope of existing planned issues, and the proposing author's authority in the field. Most pre-invitation contacts receive a yes/no response within two weeks.

Week 2 to 12: Theme-issue assembly and Guest Editor recruitment

Accepted topics enter the theme-issue calendar. The Editor-in-Chief or an Executive Editor recruits a Guest Editor (often the proposing author for single-issue topics) who then assembles a slate of invited contributors. Each invited author receives an Editorial Manager link, a deadline, and a target page range.

Week 12 to 36: Invited manuscript writing and submission

Invited authors typically have 6-9 months to write and submit. Editorial Manager intake performs the standard technical check; the manuscript then routes to the Guest Editor and Executive Editor for substantive review.

Week 36 to 52: External peer review, revision, and publication

Invited theme-issue manuscripts go to 2-3 external reviewers. Median time from invitation to publication is 6-12 months. Authors who deliver on time and meet the editorial standard are typically published; revision cycles add 6-12 weeks each.

• Is Advanced Drug Delivery Reviews a good journal?

• Acta Biomaterialia Submission Guide for biomaterial-delivery papers where the main claim depends on biological validation of a material system.

Before contacting the editor, run your proposal through an ADDR pre-invitation readiness check.

This page handles the public submission rules; the draft still needs a journal-specific fit check. The review tells you whether your paper clears the Advanced Drug Delivery Reviews fit check before upload, especially around thematic-issue calendar mismatch, author standing in adjacent rather than central drug delivery, and topic timing collisions. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Across Manusights submission reviews for proposals targeting ADDR, three patterns generate the most consistent declines.

Manusights pre-submission pattern analysis shows many ADDR declines trace to thematic-issue calendar mismatch. The same pattern analysis often finds these cases involve author-authority gaps. A related pattern is that these cases often arise from topic timing collisions.

Thematic-issue calendar mismatch

ADDR plans thematic issues 12-18 months ahead. We observe contacts proposing topics that don't align with planned themes routinely declined.

Check thematic issue calendar mismatch before submitting to Advanced Drug Delivery Reviews →

Author standing in adjacent rather than central drug delivery

Guest Editors weigh authority heavily.

Check author standing in adjacent rather than central drug delivery before submitting to Advanced Drug Delivery Reviews →

Topic timing collisions

ADDR editors check recent thematic issues. A ADDR pre-invitation readiness check can identify whether the timing and authority case is strong.

Clarivate JCR 2024 bibliometric data places ADDR among top pharmaceutical-research journals.

Check topic timing collisions before submitting to Advanced Drug Delivery Reviews →

In pre-invitation diagnostic work for journals at this tier, we consistently see four signals that distinguish strong proposals from weak ones. First, the proposed topic must align with what editors are publicly signaling as priority directions through recent editorials, conference participation, and society announcements. Second, the author CV should show 10+ primary-research papers in the exact subfield over the prior decade, not just adjacent-area credentials.

Third, the proposal should differentiate sharply from comprehensive coverage published in the prior 5 years; proposals that overlap a recent piece's table of contents are declined on that basis alone. Fourth, the proposal should be framed in terms of what the synthesis or research will reorganize or argue, not as comprehensive coverage of recent papers.

For Advanced Drug Delivery Reviews-targeted manuscripts, beyond the rubric checks, three pre-submission diagnostic patterns recur most often in the manuscripts we review for journals at this tier. First, abstracts that begin with context paragraphs rather than the central contribution lose force in editorial scanning. We recommend the abstract's first sentence state the paper's central finding or argument; everything else is supporting context.

Second, manuscripts where the methods section uses too much generic language (we conducted a survey, we ran an experiment) without specifying sample, design, statistical approach, and sensitivity boundaries are flagged at desk for insufficient methodological detail. Editors at this tier expect the methods section to establish that the work could be replicated by an independent team.

Third, manuscripts that lack engagement with the journal's recent issues are at risk of being told the contribution doesnt fit the publication conversation. We recommend authors review the journals last 3-5 issues before drafting and explicitly cite at least 2-3 papers from those issues.

For Advanced Drug Delivery Reviews-targeted manuscripts, the strongest proposals we coach distinguish themselves on three operational behaviors. First, they confine the cover letter to one page and use it to make the case for fit, contribution, and significance, not to summarize the abstract. Second, they include a one-sentence elevator pitch in the cover letter's opening that the editor can use when discussing the paper internally.

Third, they identify the specific recent papers in the journal that this manuscript builds on and the specific competing or contradicting work; this signals the authors are operating inside the publication conversation rather than outside it.